Inicio・Lista de Acciones・Genmab A-S

Genmab A-S

Cerrado

1,863 -0.4

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

1857.5

Máximo

1869

Métricas clave
By Trading Economics
Ingresos	21M 52M
Ventas	-184M 881M
P/B Media del Sector	21.339 56.269
BPA	8.48
Margen de beneficios	5.915
Empleados	3,088
EBITDA	-30M 215M

Recomendaciones
By TipRanks
Recomendaciones	Neutral
Estimación a 12 Meses	-1.49% downside

Dividendos
By Acuity
Próximas Ganancias	6 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	8.4B 113B
Apertura anterior	1863.4
Cierre anterior	1863

Genmab A-S Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

3 jul 2026, 23:52 UTC

U.S. job growth disappoints, reducing Fed rate hike expectations, while global equities rise amid easing U.S.-Iran tensions and stable oil prices.

3 jul 2026, 23:52 UTC

European equity indices rise as weaker U.S. job growth dampens Fed rate hike expectations, while ECB signals caution amid mixed economic indicators.

3 jul 2026, 23:52 UTC

Global equity markets rise as U.S. job growth disappoints and European economic indicators show mixed signals, prompting cautious outlook on interest rate hikes.

3 jul 2026, 23:52 UTC

Asia equity markets rise as U.S. jobs data eases Fed rate hike concerns, boosting sentiment and commodities like gold and oil.

3 jul 2026, 23:52 UTC

Brazil's Inflation Rate Release on July 10, 2026: Market Awaits Insights Amid World Cup Spending Boost and Economic Uncertainty.

3 jul 2026, 23:52 UTC

Brazil's Inflation Rate Release on July 10, 2026: Market Eyes Potential Shifts Amid Service Sector Growth and Global Pressures.

3 jul 2026, 23:41 UTC

Spain's Consumer Confidence Index Holds Steady at 77.7 Amid Geopolitical Tensions and Inflation Concerns

3 jul 2026, 23:41 UTC

Correlated Moves

Macro News

Bitcoin is gaining ground amid improved sentiment following a weaker U.S. jobs report, which has eased expectations for Federal Reserve interest rate hikes.

3 jul 2026, 23:31 UTC

Mexico's June 2026 Inflation Rate Release on July 9 Expected Amid Cautious Optimism Over Global Price Trends.

3 jul 2026, 23:31 UTC

Mexico's Inflation Rate MoM Release on July 9, 2026: Market Anticipates Impact from U.S. Monetary Policy Adjustments and Global Economic Pressures.

3 jul 2026, 23:22 UTC

U.S. Balance of Trade Report Set for July 7, Anticipating $78.8 Billion Deficit Amid Labor Market Concerns and Global Economic Volatility

3 jul 2026, 23:22 UTC

U.S. Imports Data Release on July 7, 2026: Analysts Anticipate Cautious Optimism Amid Tariff Influences and Supply Chain Concerns

3 jul 2026, 23:22 UTC

U.S. Exports Data Release on July 7, 2026, Expected to Show Continued Growth Amid Geopolitical Tensions and Trade Policy Changes

3 jul 2026, 23:22 UTC

Canada's Trade Balance Expected to Show C$2.4 Billion Surplus Amid Optimism in Export Performance and Market Uncertainty Over U.S. Trade Relations

3 jul 2026, 23:21 UTC

Correlated Moves

The Russell 2000 Index is trading lower in after-market hours, reflecting a broader market decline linked to disappointing U.S. job growth data.

3 jul 2026, 23:21 UTC

Correlated Moves

The S&P 500 Index is trading lower in after-market hours, reflecting minimal movement since Friday's close amid weaker U.S. jobs data.

3 jul 2026, 23:21 UTC

Nasdaq 100 Index declines slightly in after-market trading, remaining flat overall. Recent U.S. nonfarm payrolls report eases interest rate hike concerns.

3 jul 2026, 23:21 UTC

Correlated Moves

The Dow Jones Index is trading lower in after-market hours, reflecting a weak performance since Friday's close amid disappointing U.S. nonfarm payrolls data.

3 jul 2026, 23:21 UTC

The FTSE 100 Index is trading lower in after-market hours, with no specific news identified to explain the decline.

3 jul 2026, 23:11 UTC

Brazil's Retail Sales MoM report on July 8, 2026, signals cautious market sentiment amid recent declines and economic uncertainty.

3 jul 2026, 23:11 UTC

Correlated Moves

XRP is trading higher, buoyed by positive sentiment in the digital currency market and softer U.S. nonfarm payrolls data impacting interest rate expectations.

3 jul 2026, 23:11 UTC

Correlated Moves

Macro News

Ethereum is trading higher since Thursday, supported by increased interest in Pepeto and a correlated rise in Bitcoin. Earlier, it pulled back from a session high.

3 jul 2026, 23:01 UTC

Declining 30-Year Mortgage Rates Signal Potential Boost in U.S. Housing Market Confidence and Activity

3 jul 2026, 23:01 UTC

Terra is trading higher during Friday's session, maintaining upward momentum since Thursday. No specific news has been identified to explain this price movement.

3 jul 2026, 23:01 UTC

Cardano is trading higher today, continuing a notable increase since Thursday's close. The asset remains above its 20-day moving average.

3 jul 2026, 22:51 UTC

Brazil's Central Bank to Release Key Interest Rate Insights Amid Global Economic Influences on July 6, 2026.

3 jul 2026, 22:51 UTC

Japan's Current Account data release on July 7, 2026, forecasts a JPY 4.1 trillion surplus amid cautious market sentiment and potential currency volatility concerns.

3 jul 2026, 22:51 UTC

The DAX 30 Index is trading lower in after-market hours, with no specific news identified. Recent U.S. jobs data may be influencing market sentiment.

3 jul 2026, 22:31 UTC

UK Housing Market Faces Negative Outlook as RICS House Price Balance Forecasts -0.32% Amid Economic Pressures and Inflation Concerns

3 jul 2026, 22:11 UTC

Japan's Household Spending Data Set for Release Amidst Declining Consumer Confidence and Currency Market Volatility

Comparación entre iguales

Cambio de precio

Genmab A-S previsión

Precio Objetivo

By TipRanks

-1.49% descenso

Estimación a 12 Meses

Media 2,493.35 DKK -1.49%

Máximo 3,320 DKK

Mínimo 308.417 DKK

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Genmab A-S Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

7 ratings

Comprar

Mantener

Vender

De acuerdo con 7 analistas que ofrecen calificaciones bursátiles a para Genmab A-S Dist en los últimos 3 meses.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Genmab A-S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.